A double-blind, randomized, placebo-controlled clinical trial evaluating the efficacy and safety of ambroxol 20 mg in the treatment of pharyngeal pain in patients with viral pharyngitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17013836

Enrollment

Unknown

Registered

2017-12-11

Start date

2007-04-01

Completion date

Unknown

Last updated

2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pharyngitis

Interventions

control:placebo

case:Ambroxol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with sore throat caused by acute viral pharyngitis. 2. According to VRS (PI), sore throat strength was rated as at least "severe" in patients.

Exclusion criteria

Exclusion criteria: 1. Patients with primary bacterial pharyngitis or bacterial secondary infection (clinically seen; especially exudate assessment); 2. Acute pharyngitis The first symptom (eg sore throat) has been over 3 days; 3. Blood test white blood cell count greater than 10×10^9/L; 4. Patients with acute viral or bacterial pharyngitis in the past 4 weeks; 5. Bronchial dysfunction or accompanied by more complications of secretions (the risk of obstruction of secretions); 6. Patients who are allergic to ambroxol or the auxiliary substances contained in the tablets are known.

Design outcomes

Primary

Measure	Time frame
pain;	—

Countries

China

Contacts

Public ContactDehui Wang

EENT Hospital of Fudan University

wangdehuient@sina.com+86 021-64377134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026